Tiziana Life Sciences Ltd (TLSA) Secures U.S. DoD Grant to Advance Intranasal Foralumab for Spinal Cord Injury

In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Tiziana Life Sciences Ltd is one of them.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) is a clinical-stage biotech company focused on next-generation immunomodulation therapies for neuroinflammatory and neurodegenerative diseases, including multiple sclerosis, Alzheimer’s, and multiple system atrophy. Its lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody designed to stimulate regulatory T cells and rebalance immune function.

In September 2025, Tiziana Life Sciences Ltd drew attention with significant insider activity. CEO Ivor Elrifi purchased 193,848 shares at $1.65 each, while Executive Chairman Gabriele Cerrone added 25,000 shares, raising his stake to 36.28%. These moves underscore strong management confidence in the corporation’s pipeline and long-term prospects.

Tiziana Life Sciences Ltd (TLSA) Secures U.S. DoD Grant to Advance Intranasal Foralumab for Spinal Cord Injury

Tiziana Life Sciences Ltd also secured a U.S. Department of Defense grant on September 15, 2025, to accelerate intranasal foralumab development for spinal cord injury, expanding its immunomodulatory focus beyond central nervous system disorders. Clinically, the business reached a milestone with the dosing of the first patient in a Phase 2a trial for multiple system atrophy, following FDA approval of a Phase 2 IND application in August 2025.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW